Skip to main content
SpringerLink
Log in

Early initiation of basal insulin beneficial at no added cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Truven Health MarketScan Commercial database, Medicare Supplemental database, and Quintiles Electronic Medical Records

  2. proportion of glycosylated haemoglobin

Reference

  • Levin P, et al. Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs. Clinical Therapeutics : 8 Dec 2015. Available from: URL: http://doi.org/10.1016/j.clinthera.2015.11.011

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Early initiation of basal insulin beneficial at no added cost. PharmacoEcon Outcomes News 744, 12 (2016). https://doi.org/10.1007/s40274-016-2716-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-2716-y

Search

Navigation